Evidence map›Paper›PMID 33565282›Full record

ArticleCancer medicine2021

Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma.

Sumitaka Hagiwara, Eiichi Sasaki, Yasuhisa Hasegawa, Hidenori Suzuki, Daisuke Nishikawa, Shintaro Beppu, Hoshino Terada, Michi Sawabe, Masahide Takahashi, Nobuhiro Hanai

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Sumitaka HagiwaraDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID 0000-0003-1774-4076
Eiichi SasakiDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID 0000-0002-6385-8341
Yasuhisa HasegawaDepartment of Head and Neck Surgery - Otolaryngology, Asahi University Hospital, Gifu, Japan.ORCID 0000-0002-6635-3955
Hidenori SuzukiDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Daisuke NishikawaDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Shintaro BeppuDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Hoshino TeradaDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Michi SawabeDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Masahide TakahashiInternational Center for Cell and Gene Therapy, Fujita Health University, Toyoake, Japan.ORCID 0000-0002-2803-2683
Nobuhiro HanaiDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID 0000-0003-2524-8283
Aichi Cancer Center · JPAsahi University · JPFujita Health University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVarious biomarkers are being developed for the early diagnosis of cancer and for predicting its prognosis. The aim of this study is to evaluate the diagnostic significance of serum CD109 in head and neck squamous cell carcinoma (HNSCC).

methodsThe serum CD109 levels in a total of 112 serum samples collected before and after surgery from 56 HNSCC patients were analyzed with an enzyme-linked immunosorbent assay (ELISA). The clinical factor that showed a statistically significant association with both the preoperative serum CD109 level, and the CD109 index: which was defined as the ratio of the preoperative serum CD109 level to the postoperative serum CD109 level, were assessed. The correlations between the serum CD109 levels and lymph node density (LND), pathological features such as lymphatic invasion, and serum SCC antigen levels were also assessed.

resultsThe ELISA measurement revealed that preoperative serum CD109 levels were elevated in patients with node metastasis-positive and stage IV disease, in comparison to those with node metastasis-negative and Stage I+II+III disease, respectively. A multiple regression analysis indicated that serum CD109 level was significantly associated with the node metastasis status. A Spearman's rank correlation analysis also revealed a positive correlation between the preoperative serum CD109 level and LND. Furthermore, the probabilities of the overall and relapse-free survival were significantly lower in patients with a preoperative serum CD109 level of ≥38.0 ng/ml and a CD109 index of ≥1.6, respectively, than in others. There was no significant correlation between the serum CD109 and SCC antigen levels.

conclusionsThe serum CD109 levels were elevated in patients with advanced stage disease, reflecting the node metastasis status. CD109 in sera could be a novel prognostic marker for HNSCC involving lymph node metastasis.

Indexed as

AdultAgedAged, 80 and overAntigens, CDBiomarkers, TumorFemaleFollow-Up StudiesGPI-Linked ProteinsHead and Neck NeoplasmsHumansLymphatic MetastasisMaleMiddle AgedNeoplasm ProteinsPrognosisRetrospective StudiesAntigens, CDBiomarkers, TumorCD109 protein, humanGPI-Linked ProteinsNeoplasm Proteinscancer biomarkerenzyme-linked immunosorbent assayhead and neck squamous cell carcinomanode metastasisSCC antigenserum CD109

Identifiers

PMID33565282
PMCPMC7926025
OpenAlexW3126639147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.